Sophia Genetics Teams With Spanish Diagnostics Firm, Institute on Chronic Lymphocytic Leukemia Care
The partners have developed an application on Sophia's DDM platform that improves the integration of genomic research results into CLL patient care.
Sophia Genetics Q2 Revenue Grows 72 Percent
In its first quarterly report as a public company, Sophia reported a net loss of $18.4 million, in part due to higher expenses related to its July IPO.
Sophia Genetics Raises $234M in IPO, Eyes Additional Partnerships
The stock opened at $18 per share, valuing the Switzerland- and Boston-based bioinformatics company at $1.14 billion.
Sophia Genetics Increases IPO Target to $221M
The company will now offer 13 million common shares at $17 to $19 per share, raising its proceeds target from the previously announced $100 million.
Sema4 Raises $121M in Series C Financing Round
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.